Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

Phase 1

Completed

• Conditions: Breast Cancer; Ovarian Cancer; Malignant Pleural Effusion; Lung Cancer; Mesothelioma
• Interventions: Biological: AdV-tk + valacyclovir

• Registration Number: NCT01997190
• Lead Sponsor: Candel Therapeutics, Inc.

Brief Summary

This is a phase I study of intrapleural AdV-tk therapy in patients with malignant pleural effusion (MPE). The primary objective is to test the safety of intrapleural AdV-tk therapy. Secondary objectives are to evaluate clinical efficacy and biologic activity

Detailed Description

The goal of this open-label, dose escalation clinical trial is to investigate if the administration of AdV-tk to patients with MPE followed by valacyclovir and chemotherapy is safe, can be effectively delivered without disturbing standard therapy, and will have anti-tumor activity in patients with solid tumors.

The first and second dose levels have been completed, and the study is currently expanded to enroll more patients to dose level 2 with Celecoxib.

Patients will receive one injection of AdV-tk through a pleural catheter on day 0. The prodrug, valacyclovir, will be administered orally at a fixed dose for 14 days after each AdV-tk injection. Celecoxib will be administered starting 3 days before AdV-tk and continuing for 2 days after AdV-tk administration.

Chemotherapy may begin at any time after completion of valacyclovir. Choice of chemotherapy depends on the treating oncologist.

Study Timeline

• Study Start: 2013-10
• Study First Submitted: 2013-11-19
• Study First Submitted QC: 2013-11-22
• Study First Posted: 2013-11-28
• Primary Completion: 2015-12
• Study Completion: 2018-02
• Status Verified: 2023-08
• Last Update Submitted: 2023-08-23
• Last Update Posted: 2023-08-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

• Patients must have MPE (defined as positive pleural fluid cytology). Eligible patients include NSCLC, small cell lung cancer, malignant mesothelioma (MM), breast cancer and ovarian cancer. Diagnosis must be made prior to AdV-tk injection. For patients with MM, histologic proof is needed, but positive pleural fluid cytology is not required.
• Patients must have an indication for placement of pleural catheter
• Patients must be 18 years of age or older
• Performance status must be ECOG 0-1
• Acute toxic effects from any prior radiotherapy, chemotherapy, or prior surgical procedures must have resolved to NCI CTCAE v 4.0 grade ≤ 1
• Baseline pulmonary function tests must be FEV1 ≥1 liter or 40% of predicted value (may be post-drainage and/or bronchodilator)
• Bilirubin ≤ 1.5 x upper limit of normal (ULN) and ALT, AST and alkaline phosphatase ≤ 2 x ULN
• Serum creatinine < 2 mg/dl and calculated creatinine clearance > 30 ml/min
• Hemoglobin ≥ 9 g/dL, ANC > 1000/mm3 and platelets > 100,000/mm3
• Serum albumin level ≥ 2.5 g/dL
• Patients must give study specific informed consent prior to enrollment

Exclusion Criteria

• Patients may not be on systemic corticosteroids (>10 mg prednisone per day) or other systemic immunosuppressive drugs
• Patient is not known to be HIV+
• Patient is not pregnant or breast-feeding. Female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapy.
• Patient may not have clinically significant pericardial effusion
• Patient may not have other serious co-morbid illness or compromised organ function
• Patient may not have liver disease including known cirrhosis, active hepatitis or chronic active hepatitis B
• No prior allergic reaction or hypersensitivity to sulfonamides, celecoxib, aspirin or other NSAIDs
• No concurrent use of other NSAID or aspirin exceeding 100mg/day during celecoxib administration. No wash-out period required.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Study Arm	AdV-tk + valacyclovir	AdV-tk + valacyclovir

Primary Outcome Measures

Name	Time	Method
Incidence of treatment emergent adverse events	8 weeks

Secondary Outcome Measures

Name	Time	Method
Progression-free survival	5 years
Overall survival	10 years

Trial Locations

Locations (1)

University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States